Irbesartan Hexal

Irbesartan, the active ingredient in Irbesartan Hexal, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetes‑related kidney disease. It reduces vascular resistance and aldosterone secretion, helping to lower systolic and diastolic pressures.

GNH USA supplies Irbesartan Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Irbesartan acts on the renin‑angiotensin system to treat conditions related to elevated blood pressure and renal impairment. - Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Cardiovascular risk reduction: may decrease incidence of stroke and heart failure in hypertensive patients with left ventricular hypertrophy.

Irbesartan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema - Acute renal failure - Severe hyperkalemia - Hepatic injury

When prescribing Irbesartan, clinicians should consider several precautionary measures to ensure patient safety. - Monitor blood pressure: adjust dose to achieve target levels. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. - Use caution in hepatic impairment: dose may need adjustment. - Contraindicated in pregnancy: avoid use due to risk of fetal toxicity. - Store at below 25°C: keep in the original pack, protect from moisture.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (dual renin‑angiotensin blockade): increase risk of renal impairment and hypotension. - Concurrent ACE inhibitor or ARB therapy: may cause excessive potassium rise and renal dysfunction. - Potassium‑sparing diuretics: elevate risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: increased lithium levels, risk of toxicity. - Thiazide diuretics: additive blood‑pressure lowering effect, monitor for hypotension.